The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals director Whalen Matthew Pratt reported an option restructuring. He agreed to cancel 25,000 incentive stock options with a $5.02 exercise price in exchange for 25,000 new options with a lower $1.30 exercise price, expiring on May 21, 2036. Following these transactions, he holds 25,000 incentive stock options that are fully exercisable.
Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options with no net change in option count. He agreed to cancel an existing option for 25,000 shares of common stock with a $5.02 exercise price and an expiration on August 27, 2034. In exchange, he received a new option for 25,000 shares at a lower exercise price of $1.30, expiring on May 21, 2036. These are incentive stock options granted as compensation, not open-market share purchases or sales, and he now holds 25,000 options directly following the transaction.
Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count. He agreed to cancel 25,000 fully exercisable incentive stock options for common stock with a $5.02 exercise price and a August 27, 2034 expiration, as a disposition back to the issuer.
In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market.
Telomir Pharmaceuticals, Inc. filed an 8-K describing a press release about a new peer-reviewed preclinical study of its lead candidate Telomir-1 (Telomir-Zn) in Wilson’s disease. The study, published in Advances in Redox Research, used cellular systems and an ATP7B-deficient zebrafish model.
Telomir-Zn showed dose-dependent benefits across multiple endpoints, including reduced copper-associated oxidative stress, lower hepatic copper burden, improved liver injury biomarkers such as ALT, AST and bilirubin, attenuated intracellular calcium dysregulation, better locomotor performance, reduced hepatorenal tissue degeneration, and improved survival.
This is Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data supporting its mechanism of modulating intracellular copper and redox pathways. The company notes these pathways are also relevant to its Telomir-Zn program in Triple-Negative Breast Cancer, which has FDA IND clearance for a Phase 1/2 trial.
Telomir Pharmaceuticals reported a Q1 2026 net loss of $0.99 million with no revenue, reflecting its early-stage biotech focus on Telomir-1 (Telomir-Zn) for cancer and age-related diseases. Operating costs were $1.04 million, with general and administrative expenses falling sharply year over year as prior stock-based compensation stepped down, while research and development rose modestly as preclinical and clinical work progressed.
Cash was $5.6 million as of March 31, 2026 after using about $1.8 million in operating cash during the quarter, leaving stockholders’ equity of roughly $5.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without new capital. After quarter-end, Telomir closed its merger with related-party TELI Pharmaceuticals, issuing 34,389,710 restricted shares and securing a $1.0 million cash contribution plus a binding commitment for up to an additional $4.0 million tied to Telomir-1 development milestones. A small at-the-market sale added about $6,000 of proceeds.
Telomir Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir‑Zn, the company’s lead product candidate, to treat advanced or metastatic triple‑negative breast cancer.
The company plans a first‑in‑human Phase 1/2 trial starting in the first half of 2026, enrolling about 76 patients. Phase 1 will focus on safety, tolerability, dose‑limiting toxicities, pharmacokinetics, pharmacodynamics, and early antitumor activity to determine the recommended Phase 2 dose. Phase 2 will assess preliminary efficacy, with objective response rate as the primary endpoint and duration of response, progression‑free survival, overall survival, and safety as key secondary endpoints.
The trial will feature an extensive translational biomarker program to study epigenetic regulation, gene expression, histone modification, and telomere‑related biology, aiming to link target engagement and biomarker changes with clinical outcomes in triple‑negative breast cancer.
Telomir Pharmaceuticals CEO and Chairman Erez Aminov reported a restructuring-related share exchange rather than an open-market trade. He is shown with 7,319,710 shares of common stock at a reported value of $1.3700 per share following the transaction. A footnote explains these Telomir shares were issued to him in exchange for his shares of TELI Pharmaceuticals, Inc. in connection with Telomir’s acquisition of TELI, so the filing reflects how his prior TELI ownership converted into Telomir equity.
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, issuing 34,389,710 restricted shares of common stock to TELI’s former shareholders. The share count was based on an exchange ratio derived from independent third-party valuations of both companies.
At closing, Bayshore Trust contributed $1 million to Telomir and entered into an option to pay up to $4 million more for Telomir shares if milestones are met, including FDA acceptance of an Investigational New Drug application and initiation of a Phase 1/2 study for Telomir-1. The deal consolidates all global rights to Telomir-1 under Telomir, giving it full control over development and potential commercialization across major international markets.
Telomir Pharmaceuticals, Inc. reported that on March 30, 2026 it received a letter from the Nasdaq Capital Markets confirming the company is now in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders. Nasdaq has determined the matter is closed, meaning Telomir’s listing status related to this meeting requirement is no longer in question.
Telomir Pharmaceuticals, Inc. submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate Telomir-1 (Telomir-Zn) to treat advanced and metastatic triple-negative breast cancer (TNBC). If the IND is cleared, the company plans a Phase 1/2 trial of Telomir-1 as an oral monotherapy.
The Phase 1 portion is expected to use a standard 3+3 dose-escalation design to assess safety, tolerability, dose-limiting toxicities, and select a recommended Phase 2 dose. Phase 2 is expected to use a Simon two-stage design focused on objective response rate as the primary endpoint.
Telomir-1 is described as a first-in-class metal-modulating epigenetic therapy designed to reduce redox-active iron and increase zinc availability, inhibiting iron-dependent epigenetic enzymes such as histone demethylases. The company reports preclinical data showing reduced tumor growth and metastasis in TNBC models, iron-dependent tumor cell death in several human TNBC cell lines, and GLP safety studies with no treatment-related adverse or dose-limiting toxicities observed.